4.0 Review

Parkinson's Psychosis

期刊

CURRENT TREATMENT OPTIONS IN NEUROLOGY
卷 12, 期 3, 页码 200-211

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11940-010-0072-y

关键词

-

资金

  1. AstraZeneca
  2. Forest Laboratories
  3. Huntington Study Group
  4. Michael J. Fox Foundation
  5. Movement Disorders Society
  6. National Parkinson Foundation
  7. NIH/NINDS
  8. Novartis
  9. Parkinson Study Group
  10. Society of Progressive Supranuclear Palsy
  11. Solvay
  12. Teva
  13. NATIONAL INSTITUTE ON AGING [T32AG020499] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Psychosis is a leading reason for nursing home placement of patients with Parkinson's disease (PD). It may also be the single greatest stressor for caregivers of PD patients, it is generally persistent, and its presence markedly increases the risk of mortality. For these reasons, it is essential to recognize and appropriately treat psychosis in PD. Treatment of psychotic symptoms should be initiated after potential medical and environmental causes of delirium (eg, infection) have been eliminated or addressed. Initial pharmacologic changes should include limiting the patient's anti-PD medications to those that are necessary to preserve motor function (ie, eliminating adjunctive agents). Should that fail, an atypical antipsychotic agent is the treatment of choice. Clozapine is presently the gold standard, and quetiapine represents another option because of its ease of use and good tolerability profile. Emerging treatment options include the use of acetylcholinesterase inhibitors, antidepressants, and cognitive behavioral therapy. This article reviews what is currently known about treatment strategies in PD psychosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据